The selective VDR activation with paricalcitol for the reduction of albuminuria in patients with type 2 diabetes (VITAL study) demonstrated the additional antiproteinuric effect of paricalcitol in diabetic patients on stable treatment of RAAS inhibition, suggesting the comparable synergistic effect in patients with DN [79]. This evidence concerns the gene VDR and type 2 diabetes mellitus.